GoldenGolden
Advanced Search
Evvivax

Evvivax

A biotechnology company that is a subsidiary of Takis and is developing a number of immunotherapies for veterinary purposes. It was founded in 2016 and is located in Rome, Italy.

Evvivax is a Rome-based veterinary biotechnology company that gets its name from Engineered Veterinary Vectored Immunotherapy and Vaccines. The company researches and develops nucleic-acid based therapies, completes process development, provides industrial scale production and conducts clinical trials. Its technologies include genetic vaccines as well as in vivo electroporation.

COVID-19

The company is in a pre-clinical stage study of a genetic vaccine for COVID-19. It is working with its parent company, Takis, to conduct the research.

Timeline

May 6, 2021
Applied DNA and Evvivax announces that LinearDNATM COVID-19 vaccine candidate booster yields 5-fold average increase in neutralizing antibody titers in domestic felines.

Products

People

Name
Role
LinkedIn

Luigi Aurisicchio

CEO

Further reading

Title
Author
Link
Type
Date

CORONAVIRUS - Takis and Evvivax developing a 2019-nCoV Coronavirus vaccine

Web

February 4, 2020

LineaRx and Takis/Evvivax Anti-Cancer Vaccine Candidates Demonstrate Tumor Reduction

Web

September 19, 2019

Documentaries, videos and podcasts

Title
Date
Link

Elephant in the Room Short Version

October 15, 2017

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
May 6, 2021
BioSpace
Applied DNA and Evvivax Announce that LinearDNATM COVID-19 Vaccine Candidate Booster Yields 5-Fold Average Increase in Neutralizing Antibody Titers in Domestic Felines - read this article along with other careers information, tips and advice on BioSpace

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.